Antiplatelet therapy following transcatheter aortic valve implantation

Heart

Volumn 101, Issue 14, 2015, Pages 1118-1125

  Hassell, Mariëlla E C J ^a   Hildick Smith, David ^b   Durand, Eric ^c   Kikkert, Wouter J ^a   Wiegerinck, Esther M A ^a   Stabile, Eugenio ^d   Ussia, Gian Paolo ^e   Sharma, Sumeet ^b   Baan, Jan ^a   Eltchaninoff, Hélène ^c   Rubino, Paolo ^f   Barbanti, Marco ^g   Tamburino, Corrado ^g   Poliacikova, Petra ^b   Blanchard, Didier ^h   Piek, Jan J ^a   Delewi, Ronak ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UK   (United Kingdom)

^c HÔPITAL CHARLES NICOLLE   (France)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^f Laboratory of Invasive Cardiology   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

^h UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; AORTIC VALVE STENOSIS; BLEEDING; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DEVICES; FEMALE; HEART CATHETERIZATION; HEART VALVE REPLACEMENT; HUMAN; MALE; META ANALYSIS; MORTALITY; ODDS RATIO; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; STROKE; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; AORTIC VALVE STENOSIS; ASPIRIN; CARDIAC CATHETERIZATION; DRUG THERAPY, COMBINATION; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HUMANS; MALE; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; STROKE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84934283224     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-307053     Document Type: Article

References (19)

1. Généreux P, Head SJ, Van Mieghem NM, et al. Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions: a weighted meta-analysis of 3,519 patients from 16 studies. J Am Coll Cardiol 2012;59:2317-26.
2. Rodes-Cabau J, Dauerman HL, Cohen MG, et al. Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. J Am Coll Cardiol 2013;62:2349-59.
3. Nijenhuis VJ, Stella PR, Baan J, et al. Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals. Neth Heart J 2014;22:64-9.
4. Ussia GP, Scarabelli M, Mule M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2011;108:1772-6.
5. Stabile E, Sorropago G, Pucciarelli A, et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: A randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol 2014;174:624-7.
6. Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J 2011;32:205-17.
7. Durand E, Blanchard D, Chassaing S, et al. Comparison of two antiplatelet therapy strategies in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2014;113:355-60.
8. Gilard M, Eltchaninoff H, Iung B, et al. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med 2012;366:1705-15.
9. Poliacikova P, Cockburn J, de Belder A, et al. Antiplatelet and antithrombotic treatment after transcatheter aortic valve implantation-comparison of regimes. J Invasive Cardiol 2013;25:544-8.
10. Naber CK, Ghanem A, Abizaid AA, et al. First-in-man use of a novel embolic protection device for patients undergoing transcatheter aortic valve implantation. EuroIntervention 2012;8:43-50.
11. Duffy SW, Rohan TE, Altman DG. A method for combining matched and unmatched binary data: application to randomized, controlled trials of photocoagulation in the treatment of diabetic retinopathy. Am J Epidemiol 1989;130:371-8.
12. Nuis RJ, Van Mieghem NM, Schultz CJ, et al. Frequency and causes of stroke during or after transcatheter aortic valve implantation. Am J Cardiol 2012;109:1637-43.
13. Nombela-Franco L, Webb JG, de Jaegere PP, et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation 2012;126:3041-53.
14. Hassell ME, Nijveldt R, Roos YB, et al. Silent cerebral infarcts associated with cardiac disease and procedures. Nat Rev Cardiol 2013;10:696-706.
15. Onsea K, Agostoni P, Samim M, et al. First-in-man experience with a new embolic deflection device in transcatheter aortic valve interventions. EuroIntervention 2012;8:51-6.
16. Halliday BP, Dworakowski R, Brickham B, et al. Usefulness of periprocedural bleeding to predict outcome after transcatheter aortic valve implantation. Am J Cardiol 2012;109:724-8.
17. Van Mieghem NM, Nuis RJ, Tzikas A, et al. Prevalence and prognostic implications of baseline anaemia in patients undergoing transcatheter aortic valve implantation. EuroIntervention 2011;7:184-91.
18. Tchetche D, van der Boon RM, Dumonteil N, et al. Adverse impact of bleeding and transfusion on the outcome post-transcatheter aortic valve implantation: insights from the Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC Plus) initiative. Am Heart J 2012;164:402-9.
19. Amat-Santos IJ, Rodes-Cabau J, Urena M, et al. Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation. J Am Coll Cardiol 2012;59:178-88.